Versanis’ bimagrumab, first-in-class obesity therapy, enters Phase IIb of development
Pharmaceutical Technology
JANUARY 17, 2023
On January 12, Versanis Bio announced that enrollment had begun for its Phase IIb trial, BELIEVE (NCT05616013), which aims to study bimagrumab’s (BYM-338) efficacy and safety in the US, among other locations. Despite its high price tag, bimagrumab’s unique features set it apart from currently marketed therapies.
52 
Let's personalize your content